[Pomalidomide for multiple myeloma].
Bull Cancer. 2017 Jun 02;:
Authors: Dougé A, Lemal R, Chaleteix C
Abstract
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity. It is indicated in the treatment of refractory or relapsed multiple myeloma, associated to dexamethasone. It is available in France since 2013, following the results of different studies.
PMID: 28583668 [PubMed - as supplied by publisher]
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2r0Iylz
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.